Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Medulloblastoma 1Glioma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 15Temozolomide 13Specimen Handling 10X-Rays 8Biopsy 7Nuclear Medicine Department, Hospital 6Radiation 5Phantoms, Imaging 5erdafitinib 4ulixertinib 3trametinib 3larotrectinib 3dabrafenib 3Radiotherapy 3tipifarnib 2selpercatinib 2palbociclib 2olaparib 2ivosidenib 2ensartinib 2binimetinib 2Surgical Procedures, Operative 2Nivolumab 2D2C7-(scdsFv)-PE38KDEL 2vorasidenib 1veliparib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1temsirolimus 1tazemetostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × Diphtheria-Tetanus Vaccine × 30 days × Clear all
NCT05096481 2026-05-11

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

Nationwide Children's Hospital

Phase 2 Recruiting
120 enrolled
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡